


EXAMINER'S AMENDMENT

~~Claim Summary~~

1 – 11 (canceled)

¹
~~12.~~ (currently amended) A compound of the formula (I):



wherein

R¹ is alkyl having 1 to 4 carbons or halogen;

R² is alkyl having 1 to 4 carbons;

R³ is hydrogen or hydroxy; and

A is oxygen or ~~C(R⁴)(R⁵);~~

~~R⁴ is alkyl having 1 to 4 carbons or hydrogen; and~~

~~R⁵ is alkyl having 1 to 4 carbons or hydroxy;~~

or a pharmaceutically acceptable salt thereof.

²
~~13.~~ (previously presented) The compound of claim 12, wherein R¹ is halogen.

³
~~14.~~ (previously presented) The compound of claim 12, wherein R² is alkyl having 1 to 2 carbons.

⁴
~~15.~~ (previously presented) The compound of claim 13, wherein R² is alkyl having 1 to 2 carbons.

⁵
~~16~~. (previously presented) The compound of claim ¹~~12~~, wherein R³ is hydroxy.

⁶
~~17~~. (previously presented) The compound of claim ²~~13~~, wherein R³ is hydroxy.

⁷
~~18~~. (previously presented) The compound of claim ⁴~~15~~, wherein R³ is hydroxy.

19. (canceled)

20. (canceled)

21. (canceled)

⁸
~~22~~. (currently amended) A compound selected from:

5-chloro-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

5-chloro-6-ethyl-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

N-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

5-bromo-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; or

5-fluoro-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

5-fluoro-*H*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

5-chloro-*N*-({1-(cyclohexylmethyl)piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; or

5-chloro-*N*-({1-[(1-hydroxycyclohexyl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

or a pharmaceutically acceptable salt thereof.

⁹
~~23~~. (previously presented) A pharmaceutical composition comprising a compound of claim ¹~~12~~ or a pharmaceutically acceptable salt thereof together with at least one pharmaceutically acceptable carrier.

24. (canceled)

/CC/
11/19/09

¹⁰
~~25.~~ (previously presented) A method for treating gastroesophageal reflux disease, ~~gastrointestinal disease~~, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), ~~constipation~~, dyspepsia, esophagitis, ^{and} ~~gastroesophageal~~ ~~disease~~, nausea, ~~central nervous system disease~~, ~~Alzheimer's disease~~, ~~cognitive disorder~~, ~~emesis~~, ~~migraine~~, ~~neurological disease~~, ~~pain~~, ~~diabetes~~, ~~apnea syndrome~~, ~~cardiac failure~~, or ~~heart arrhythmia~~ comprising administering to a mammal in need of such treatment a therapeutically effective mount of a compound according to claim ¹~~12~~ or a pharmaceutically acceptable salt thereof.

¹¹
~~26.~~ (previously presented) A method for treating gastroesophageal reflux disease comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim ¹~~12~~ or a pharmaceutically acceptable salt thereof.